The CU Anschutz Campus.

Disrupting the status quo. Challenging convention. Discovering breakthroughs in healthcare.

As one of the few health destinations with renowned research, clinical studies and education programs and two top-ranked hospitals located on a single campus, CU Anschutz challenges conventional thinking from every direction. Our singular environment and highly collaborative approach to furthering innovative healthcare and medical solutions brings life-changing discoveries and treatments to fruition in an ecosystem that reaches patients faster, and empowers faculty, staff, students and providers to make an impact now and over the long term.

 
 
Screen Shot 2020-10-27 at 2.38.18 PM.jpg

The University of Colorado Anschutz Medical Campus is the academic health sciences campus in Aurora, Colorado that houses the University of Colorado's six health sciences-related schools and colleges. Aurora Oncology’s offices are located in the Bioscience I building on campus allowing close collaboration with the University’s faculty.

 

A team of entrepreneurs.

Drs. Glodé, Zinnen, and Duke have been involved with over a dozen start-up ventures at the University of Colorado.

 
brooke-cagle-JBwcenOuRCg-unsplash.jpg

Did you know?

The University of Colorado Anschutz Medical Campus has been awarded $4 million over the next four years from the National Institutes of Health (NIH) Research Evaluation and Commercialization Hubs (REACH) grant. As a result, the university is now part of a national network of research institutions sharing best practices around commercialization of academic discoveries.

 

Richard Duke, PhD and Professor of Oncology leads REACH

Richard Duke, PhD, the principal investigator on the Colorado REACH hub grant and a faculty member in the CU School of Medicine Division of Medical Oncology stated, “Having been a biomedical researcher and academic entrepreneur at CU Anschutz for nearly 40 years, I am excited to witness the translation of the numerous and varied inventions of my faculty colleagues into products that impact patients’ lives, which the REACH grant funding will support.”.

Next
Next

Tom Flaig, MD Chairs the NCCN Bladder Panel.